157 related articles for article (PubMed ID: 33304848)
1. The Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis.
Lauk O; Bruestle K; Neuer T; Battilana B; Nguyen TDL; Frauenfelder T; Stahel R; Weder W; Curioni-Fontecedro A; Opitz I
Front Oncol; 2020; 10():588563. PubMed ID: 33304848
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of pemetrexed and bevacizumab intrapleural injection for malignant pleural mesothelioma-mediated malignant pleural effusion.
Chen D; Li X; Zhao H; Fu Y; Yao F; Hu J; Du N
Indian J Cancer; 2014 Mar; 51 Suppl 3():e82-5. PubMed ID: 25818740
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Mencoboni M; Botta M; Grossi F; Cortinovis D; Zilembo N; Ripa C; Tiseo M; Favaretto AG; Soto-Parra H; De Vincenzo F; Bruzzone A; Lorenzi E; Gianoncelli L; Ercoli B; Giordano L; Santoro A
Br J Cancer; 2013 Aug; 109(3):552-8. PubMed ID: 23860535
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
5. Macroscopic complete resection is not associated with improved survival in patients with malignant pleural mesothelioma.
Batirel HF; Metintas M; Caglar HB; Ak G; Yumuk PF; Ahiskali R; Bozkurtlar E; Bekiroglu N; Lacin T; Yildizeli B; Yuksel M
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2724-2733. PubMed ID: 29510939
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of the Efficacy of Pemetrexed Maintenance Therapy in Patients with
Malignant Pleural Mesothelioma].
Zeng X; Jiang Z; Duan J
Zhongguo Fei Ai Za Zhi; 2022 Jan; 25(1):7-13. PubMed ID: 35078279
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
[TBL] [Abstract][Full Text] [Related]
9. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience.
Lang-Lazdunski L; Bille A; Papa S; Marshall S; Lal R; Galeone C; Landau D; Steele J; Spicer J
J Thorac Cardiovasc Surg; 2015 Feb; 149(2):558-65; discussion 565-6. PubMed ID: 25726878
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study.
Nakano T; Kuribayashi K; Kondo M; Morise M; Tada Y; Hirano K; Hayashi M; Tanaka M; Hirabayashi M
Asia Pac J Clin Oncol; 2021 Jun; 17(3):264-272. PubMed ID: 32893992
[TBL] [Abstract][Full Text] [Related]
11. Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Eberst G; Anota A; Scherpereel A; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Léna H; Rivière F; Monnet I; Gounant V; Janicot H; Gervais R; Locher C; Charton E; Morin F; Zalcman G; Westeel V;
Clin Cancer Res; 2019 Oct; 25(19):5759-5765. PubMed ID: 31175096
[TBL] [Abstract][Full Text] [Related]
12. Interim results of pleurectomy/decortication and intraoperative intrapleural hyperthermic cisplatin perfusion for patients with malignant pleural mesothelioma intolerable to extrapleural pneumonectomy.
Ishibashi H; Kobayashi M; Takasaki C; Okubo K
Gen Thorac Cardiovasc Surg; 2015 Jul; 63(7):395-400. PubMed ID: 25750109
[TBL] [Abstract][Full Text] [Related]
13. Predictors of long-term survival following radical surgery for malignant pleural mesothelioma.
Nakas A; Waller D
Eur J Cardiothorac Surg; 2014 Sep; 46(3):380-5; discussion 385. PubMed ID: 24482386
[TBL] [Abstract][Full Text] [Related]
14. Induction Chemotherapy Followed by Pleurectomy Decortication and Hyperthermic Intraoperative Chemotherapy (HITHOC) for Early-Stage Epitheliod Malignant Pleural Mesothelioma-A Prospective Report.
Bongiolatti S; Mazzoni F; Salimbene O; Caliman E; Ammatuna C; Comin CE; Antonuzzo L; Voltolini L
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884251
[TBL] [Abstract][Full Text] [Related]
15. Extended Pleurectomy-Decortication-Based Treatment for Advanced Stage Epithelial Mesothelioma Yielding a Median Survival of Nearly Three Years.
Friedberg JS; Simone CB; Culligan MJ; Barsky AR; Doucette A; McNulty S; Hahn SM; Alley E; Sterman DH; Glatstein E; Cengel KA
Ann Thorac Surg; 2017 Mar; 103(3):912-919. PubMed ID: 27825687
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
Dowell JE; Dunphy FR; Taub RN; Gerber DE; Ngov L; Yan J; Xie Y; Kindler HL
Lung Cancer; 2012 Sep; 77(3):567-71. PubMed ID: 22770372
[TBL] [Abstract][Full Text] [Related]
17. Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
Mordant P; McRae K; Cho J; Keshavjee S; Waddell TK; Feld R; de Perrot M
Eur J Cardiothorac Surg; 2016 Sep; 50(3):433-8. PubMed ID: 27005976
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial.
Zhan M; Zheng H; Xu T; Yang Y; Li Q
Lung Cancer; 2017 Aug; 110():1-6. PubMed ID: 28676211
[TBL] [Abstract][Full Text] [Related]
19. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
